Precision radiation and immunotherapy join forces against inoperable stomach cancer
NCT ID NCT07607119
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing a new way to give radiation therapy (called PULSAR) along with standard chemotherapy and immunotherapy for people with advanced stomach cancer that cannot be removed with surgery. The radiation is given in high doses every few weeks, tailored to each patient's tumor. The goal is to see if this combination can stop the cancer from growing for at least a year. The study plans to enroll 53 adults with a specific type of stomach cancer (HER2-negative, EBV-negative, and microsatellite stable).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PULSAR (personalized radiation therapy) combined with immunotherapy and standard systemic therapy
What this could lead to
If successful, this could offer a new treatment option for people with advanced gastric cancer that cannot be removed by surgery, potentially delaying disease progression.
What could go wrong
This is a small, early-phase study (53 people) at a single center, so results may not apply broadly. The combination of radiation and immunotherapy may cause side effects, and it is not yet known if it will improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, Select Province/State, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••